Arcutis Biotherapeutics (ARQT) Competitors $14.55 +0.21 (+1.46%) Closing price 07/22/2025 04:00 PM EasternExtended Trading$14.38 -0.17 (-1.14%) As of 07/22/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARQT vs. ELAN, RGC, LEGN, RVMD, GRFS, TGTX, NUVL, LNTH, RYTM, and AXSMShould you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include Elanco Animal Health (ELAN), Regencell Bioscience (RGC), Legend Biotech (LEGN), Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Rhythm Pharmaceuticals (RYTM), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Arcutis Biotherapeutics vs. Its Competitors Elanco Animal Health Regencell Bioscience Legend Biotech Revolution Medicines Grifols TG Therapeutics Nuvalent Lantheus Rhythm Pharmaceuticals Axsome Therapeutics Elanco Animal Health (NYSE:ELAN) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends. Which has more volatility and risk, ELAN or ARQT? Elanco Animal Health has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Which has higher earnings and valuation, ELAN or ARQT? Elanco Animal Health has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElanco Animal Health$4.44B1.67$338M$0.7420.22Arcutis Biotherapeutics$212.82M8.15-$140.04M-$1.04-13.99 Do insiders & institutionals believe in ELAN or ARQT? 97.5% of Elanco Animal Health shares are held by institutional investors. 0.9% of Elanco Animal Health shares are held by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer ELAN or ARQT? In the previous week, Elanco Animal Health had 12 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 17 mentions for Elanco Animal Health and 5 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.14 beat Elanco Animal Health's score of 1.05 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ELAN or ARQT? Elanco Animal Health currently has a consensus price target of $16.00, indicating a potential upside of 6.92%. Arcutis Biotherapeutics has a consensus price target of $18.80, indicating a potential upside of 29.21%. Given Arcutis Biotherapeutics' higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elanco Animal Health 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Is ELAN or ARQT more profitable? Elanco Animal Health has a net margin of 8.43% compared to Arcutis Biotherapeutics' net margin of -60.95%. Elanco Animal Health's return on equity of 7.54% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Elanco Animal Health8.43% 7.54% 3.57% Arcutis Biotherapeutics -60.95%-80.66%-32.94% SummaryElanco Animal Health beats Arcutis Biotherapeutics on 11 of the 16 factors compared between the two stocks. Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARQT vs. The Competition Export to ExcelMetricArcutis BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.71B$2.93B$5.48B$9.45BDividend YieldN/A2.49%4.01%4.03%P/E Ratio-13.9920.5328.3219.90Price / Sales8.15266.81409.9885.24Price / CashN/A41.6635.9658.29Price / Book10.787.808.325.67Net Income-$140.04M-$55.10M$3.24B$258.18M7 Day Performance-5.70%4.62%3.08%2.81%1 Month Performance1.04%17.99%10.92%13.53%1 Year Performance42.65%2.21%34.24%17.68% Arcutis Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARQTArcutis Biotherapeutics2.2218 of 5 stars$14.55+1.5%$18.80+29.2%+47.7%$1.71B$212.82M-13.99150Positive NewsELANElanco Animal Health2.0725 of 5 stars$14.88-0.2%$15.33+3.1%+17.0%$7.39B$4.44B20.109,000Analyst RevisionRGCRegencell Bioscience0.2406 of 5 stars$14.68-0.5%N/AN/A$7.29BN/A0.0010LEGNLegend Biotech3.6984 of 5 stars$39.44+1.2%$72.70+84.3%-25.3%$7.25B$627.24M-66.852,609Positive NewsAnalyst RevisionRVMDRevolution Medicines4.5797 of 5 stars$38.37+0.9%$68.00+77.2%-20.2%$7.15B$11.58M-9.59250GRFSGrifols3.3098 of 5 stars$9.72-0.2%$10.30+6.0%+22.6%$6.68B$7.81B8.3123,822Upcoming EarningsTGTXTG Therapeutics3.7308 of 5 stars$38.92+5.0%$43.80+12.5%+82.8%$6.18B$329M162.17290Positive NewsNUVLNuvalent3.3425 of 5 stars$84.59+4.5%$119.60+41.4%-0.6%$6.07BN/A-19.2740Analyst ForecastLNTHLantheus4.6909 of 5 stars$83.06+2.2%$131.20+58.0%-36.9%$5.75B$1.53B23.60700Upcoming EarningsRYTMRhythm Pharmaceuticals3.2945 of 5 stars$89.15+2.8%$91.00+2.1%+76.4%$5.67B$130.13M-31.73140AXSMAxsome Therapeutics4.7172 of 5 stars$112.33+3.1%$172.33+53.4%+19.2%$5.53B$385.69M-19.47380 Related Companies and Tools Related Companies ELAN Competitors RGC Competitors LEGN Competitors RVMD Competitors GRFS Competitors TGTX Competitors NUVL Competitors LNTH Competitors RYTM Competitors AXSM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARQT) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARQT Stock Alerts